Janone (NASDAQ:ALTS) vs. Xilio Therapeutics (NASDAQ:XLO) Head-To-Head Comparison

Janone (NASDAQ:ALTS) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings.

Profitability

This table compares Janone and Xilio Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Janone	N/A	-2,940.01%	-39.81%
Xilio Therapeutics	N/A	-211.50%	-80.31%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Janone and Xilio Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janone	0	0	0	0	0.00
Xilio Therapeutics	0	0	1	0	3.00

Xilio Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 406.33%. Given Xilio Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Xilio Therapeutics is more favorable than Janone.

Volatility and Risk

Janone has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.38, suggesting that its stock price is 138% less volatile than the S&P 500.

Insider & Institutional Ownership

6.3% of Janone shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 4.9% of Janone shares are held by company insiders. Comparatively, 5.2% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Janone and Xilio Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janone	$7.11 million	9.36	-$7.81 million	N/A	N/A
Xilio Therapeutics	$6.34 million	6.45	-$76.40 million	($1.28)	-0.62

Janone has higher revenue and earnings than Xilio Therapeutics.

Summary

Xilio Therapeutics beats Janone on 6 of the 11 factors compared between the two stocks.

About Janone

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

About Xilio Therapeutics

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.